Epoch 33: I&I Therapeutics Beyond CAR-T

Degraders, Bi-functionals, FcRN, Cytokines, Engagers, Immune Modulators

Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. The biopharmaceutical industry is witnessing a transformative era in the treatment of immunological and inflammatory diseases. 90% of the attention seems to be on B cell depletion approaches, and while that is great, there is so much more going on. Today’s review explores the latest innovations in the field, from the novel mechanisms of targeted protein degraders to the precise modulation capabilities of bi-functional antibodies and T cell engagers. We will also cover the promising developments of IL-17a, IL-23, and TNFR1 inhibitors, highlighting their critical roles in treating chronic inflammatory conditions. Additionally, we will touch on the strategic repurposing of immune modulators from oncology, such as OX40 and CD40L inhibitors.

If you're not subbed yet click the link below.  Every Thursday we are out with our FREE public/private biotech market update. Sundays are the days we focus on forward looking strategy.  Monday’s are for public equity research.  Tomorrow we will focus on Immunocore who is set to share Phase I/II ovarian cancer data from brenetafusp (PRAME/CD8) at ESMO in September.  With options pricing indicating an astounding 40% volatility, the market is bracing for significant movement.

Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!

Enough shilling for the day, lots to cover this week, let's get started!

Nexgen I&I Mechanisms Beyond CAR-T

They are going to talk about I&I therapeutic development beyond CAR-T?? YES WE ARE - tell a friend to tell a friend! The development of NOVEL immunology treatments is a critical area of research in the drug discovery world. Today we are going to set aside CAR-T and focus on everything else happening in the red hot area of I&I research. This will include:

1. Novel Oral Approaches

   1. Degraders in I&I

   2. Cytokines (IL17a, IL23, TNFR1)

Novel Biologic Approaches

1. Bifunctional antibodies

2. FcRN Agonists

3. Cytokines (IL-17a, IL-1a/b, IL-4/IL-31

4. T-Cell Engagers

5. Immune Modulators (OX40)

6. TL1A

If interested to go into detail on CAR-T for autoimmune we encourage you check out some of our previous writing:

NOVEL ORAL APPROACHES: Small Molecule Product Candidates